Clinical trials: Endometrioid Endometrial Adenocarcinoma
Carcinoma, Endometrioid, Fertility Preservation
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different…
- Trial name
- NCT06468215
- Testing
- Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Peking University People's Hospital
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Gynaecological Cancers
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
ATARI trial tests the ATR inhibitor drug ceralasertib (AZD6738) alone and in combination with either a PARP inhibitor drug called olaparib, or an anti-PD-L1 immunotherapy called durvalumab (MEDI4736) in patients with relapsed…
- Trial name
- ATARI (NCT04065269)
- Testing
- Ceralasertib, Olaparib, Durvalumab
- Where
- 9 sites in Canada, United Kingdom
- Volunteers
- 174 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Cytoreductive Surgery, Grade 3 Endometrial Endometrioid Adenocarcinoma
PET/MRI in Endometrial Cancer
This study is investigating if positron emission tomography (PET)/Magnetic resonance imaging (MRI) is more effective than the currently used imaging modalities (computed tomography [CT], or PET/CT) for high-risk endometrial…
- Conditions
- Cytoreductive Surgery, Grade 3 Endometrial Endometrioid Adenocarcinoma, High Grade Serous Carcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT05390021
- Testing
- PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent
- Sponsor
- Massachusetts General Hospital
Endometrioid Endometrial Adenocarcinoma
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are…
- Trial name
- NCT07107334
- Testing
- Glucagon-like peptide 1 receptor agonist
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Ovarian Cancer, Ovarian Carcinoma
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer
- Trial name
- NCT03748186
- Testing
- STRO-002
- Where
- 27 sites in United States, Spain
- Volunteers
- 136 people
- Sponsor
- Sutro Biopharma, Inc.
Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia
Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer
This single-arm study will evaluate the feasibility, safety, and preliminary efficacy of tirzepatide in combination with standard levonorgestrel intrauterine device (LNG-IUD) therapy in patients with endometrial intraepithelial…
- Conditions
- Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
- Trial name
- TIDE (NCT07812636)
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Milton S. Hershey Medical Center
Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer
- Trial name
- SAVE (NCT03422198)
- Testing
- Vaginal Cuff Brachytherapy, Short course vaginal cuff brachytherapy
- Where
- 5 sites in United States
- Volunteers
- 188 people
- Sponsor
- University of Utah
Ovarian Cancer, Relapsed Ovarian Cancer
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a…
- Conditions
- Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ACTOv (NCT05080556)
- Testing
- Carboplatin
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University College, London
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix).
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Recurrent Uterine Corpus Carcinoma
- Trial name
- NCT00064025
- Testing
- Laboratory Biomarker Analysis, Medroxyprogesterone, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has…
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
- Trial name
- NCT03914612
- Testing
- Carboplatin, Computed Tomography, Paclitaxel
- Where
- 397 sites in United States, Canada and 3 more
- Volunteers
- 813 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Mucinous Adenocarcinoma
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
This randomized phase II trial studies radiation therapy and cisplatin to see how well they work compared with radiation therapy alone in treating patients with endometrial cancer that has come back.
- Conditions
- Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Mucinous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma
- Trial name
- NCT00492778
- Testing
- 3-Dimensional Conformal Radiation Therapy, Cisplatin, Intensity-Modulated Radiation Therapy
- Where
- 441 sites in United States, Canada
- Volunteers
- 165 people
- Sponsor
- GOG Foundation
Endometrial Cancer, Endometrioid Adenocarcinoma
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.
- Conditions
- Endometrial Cancer, Endometrioid Adenocarcinoma, Endometrial Cancer Stage I
- Trial name
- NCT04291612
- Testing
- Physical exam
- Where
- 18 sites in United States, Czechia and 3 more
- Volunteers
- 1,715 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory).
- Conditions
- Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT04719273
- Testing
- Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Thomas Jefferson University
Endometrial Carcinoma, Endometrial High Grade Endometrioid Adenocarcinoma
Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in…
- Conditions
- Endometrial Carcinoma, Endometrial High Grade Endometrioid Adenocarcinoma, Stage II Endometrial Cancer, Stage III Endometrial Cancer
- Trial name
- NCT07062016
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Endometrial Cancer, Metastasis
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to rise, in part due to the obesity epidemic.
- Conditions
- Endometrial Cancer, Metastasis, Endometrioid Endometrial Cancer, Carcinosarcoma
- Trial name
- NCT05542407
- Testing
- Atezolizumab, ONC201
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
This pilot phase IIa trial studies how well exemestane works in treating patients with complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or low grade endometrial cancer.
- Conditions
- Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT03300557
- Testing
- Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent).
- Conditions
- Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT05231122
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
This phase II trial studies how well enzalutamide, carboplatin, and paclitaxel work in treating patients with endometrioid endometrial cancer that is stage III-IV or has come back.
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7
- Trial name
- NCT02684227
- Testing
- Carboplatin, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
This phase Ib/II trial tests the safety, side effects, best dose, and effectiveness of the combination of ipatasertib with megestrol acetate to megestrol acetate alone in patients with endometrial cancer that has come back…
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT05538897
- Testing
- Biospecimen Collection, Computed Tomography, Ipatasertib
- Where
- 152 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)